Advertisement
ATYR vs NVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Hold and NVO is a Buy.
ATYR in -6.58% downward trend, declining for three consecutive days on October 19, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ATYR declined for three days, in 273 of 319 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for ATYR entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
ATYR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.348) is normal, around the industry mean (3.009). P/E Ratio (-0.275) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (196.078) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ATYR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATYR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NVO's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for NVO turned positive on October 08, 2026. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in 41 of 53 cases over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVO's RSI Indicator exited the oversold zone, 20 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on NVO as a result. In 58 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
Following a +3.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in 208 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for NVO moved below the 200-day moving average on September 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
NVO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVO entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.785) is normal, around the industry mean (-3.286). P/E Ratio (1.498) is within average values for comparable stocks, (20.679). Projected Growth (PEG Ratio) (4.416) is also within normal values, averaging (5.738). Dividend Yield (0.047) settles around the average of (0.041) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
ATYR | NVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 56 Fair valued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 19 | |
PRICE GROWTH RATING 1..100 | 96 | 74 | |
P/E GROWTH RATING 1..100 | 7 | 96 | |
SEASONALITY SCORE 1..100 | 30 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ATYR's Valuation (56) in the null industry is in the same range as NVO (61) in the Pharmaceuticals Major industry. This means that ATYR’s stock grew similarly to NVO’s over the last 12 months.
ATYR's Profit vs Risk Rating (100) in the null industry is in the same range as NVO (100) in the Pharmaceuticals Major industry. This means that ATYR’s stock grew similarly to NVO’s over the last 12 months.
NVO's SMR Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for ATYR (99) in the null industry. This means that NVO’s stock grew significantly faster than ATYR’s over the last 12 months.
NVO's Price Growth Rating (74) in the Pharmaceuticals Major industry is in the same range as ATYR (96) in the null industry. This means that NVO’s stock grew similarly to ATYR’s over the last 12 months.
ATYR's P/E Growth Rating (7) in the null industry is significantly better than the same rating for NVO (96) in the Pharmaceuticals Major industry. This means that ATYR’s stock grew significantly faster than NVO’s over the last 12 months.
| ATYR | NVO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 74% |
| Stochastic ODDS (%) | N/A | 1 day ago 61% |
| Momentum ODDS (%) | N/A | 1 day ago 69% |
| MACD ODDS (%) | N/A | 1 day ago 77% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 68% |
| Advances ODDS (%) | N/A | 6 days ago 65% |
| Declines ODDS (%) | 2 days ago 86% | 2 days ago 67% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ATYR’s FA Score shows that 1 FA rating(s) are green while NVO’s FA Score has 1 green FA rating(s).
- ATYR’s FA Score: 1 green, 4 red.
- NVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ATYR’s TA Score shows that 2 TA indicator(s) are bullish while NVO’s TA Score has 4 bullish TA indicator(s).
- ATYR’s TA Score: 2 bullish, 2 bearish.
- NVO’s TA Score: 4 bullish, 5 bearish.
Price Growth
ATYR (@Biotechnology) experienced а -13.82% price change this week, while NVO (@Pharmaceuticals: Major) price change was +3.39% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.24%. For the same industry, the average monthly price growth was -4.88%, and the average quarterly price growth was +5.33%.
Reported Earning Dates
ATYR is expected to report earnings on Nov 05, 2026.
NVO is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-0.45% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+3.24% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
NVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVO has been loosely correlated with TECH. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if NVO jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To NVO | 1D Price Change % | ||
|---|---|---|---|---|
| NVO | 100% | +2.42% | ||
| TECH - NVO | 36% Loosely correlated | +0.12% | ||
| GMAB - NVO | 35% Loosely correlated | +1.48% | ||
| AXON - NVO | 29% Poorly correlated | +2.49% | ||
| IMTX - NVO | 29% Poorly correlated | +6.52% | ||
| ATYR - NVO | 28% Poorly correlated | +0.93% | ||
More | ||||